Literature DB >> 33394259

Identification of chemoresistance-associated microRNAs and hub genes in breast cancer using bioinformatics analysis.

Ming Wu1, Yujie Zhao1, Nanxi Peng1, Zuo Tao1, Bo Chen2.   

Abstract

Breast cancer threatens women's health. Although there are a lot of methods to treat breast cancer, chemotherapy resistance still hinders the effectiveness of treatment. This study attempts to explore the mechanism of chemotherapy resistance from the perspective of miRNA and look for several new targets for developing new drugs. Three datasets (GSE73736, GSE71142 and GSE6434) from Gene Expression Omnibus (GEO) were used for the bioinformatics analysis. Differentially expressed miRNAs (DE-miRNAs) and differentially expressed genes (DE-genes) were obtained by using R package "limma". DAVID tool was used to perform gene ontology annotation analysis (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for the overlapping genes. Protein-protein interaction (PPI) network was established by STRING database and visualized by software Cytoscape. Hub genes were identified by software Cytoscape. The prognostic value of hub genes was assessed through Kaplan-Meier plotter website. In total, 22 DE-miRNAs, 1932 DE-genes and top 10 hub genes were obtained. The genes were mainly enriched in cell signaling pathways like ErbB signaling pathway and PI3K / AKT/mTOR pathway. These pathways have a significant impact on the proliferation, invasion and drug resistance in cancer. MiRNA-Gene interaction may provide new insight for exploring the mechanism of chemotherapy resistance in breast cancer. Our study ultimately identified effective biomarkers and potential drug targets, which may enhance the effect of chemotherapy in patients with breast cancer.

Entities:  

Keywords:  Bioinformatics analysis; Breast cancer; Chemotherapy; Drug resistance; miRNA

Mesh:

Substances:

Year:  2021        PMID: 33394259     DOI: 10.1007/s10637-020-01059-1

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  21 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  MiR-3613-3p from carcinoma-associated fibroblasts exosomes promoted breast cancer cell proliferation and metastasis by regulating SOCS2 expression.

Authors:  Yonglei Liu; Yanfei Yang; Junxian Du; Dong Lin; Feng Li
Journal:  IUBMB Life       Date:  2020-04-28       Impact factor: 3.885

3.  Breast cancer statistics, 2019.

Authors:  Carol E DeSantis; Jiemin Ma; Mia M Gaudet; Lisa A Newman; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-10-02       Impact factor: 508.702

Review 4.  Breast cancer.

Authors:  Nadia Harbeck; Frédérique Penault-Llorca; Javier Cortes; Michael Gnant; Nehmat Houssami; Philip Poortmans; Kathryn Ruddy; Janice Tsang; Fatima Cardoso
Journal:  Nat Rev Dis Primers       Date:  2019-09-23       Impact factor: 52.329

Review 5.  The multilayered complexity of ceRNA crosstalk and competition.

Authors:  Yvonne Tay; John Rinn; Pier Paolo Pandolfi
Journal:  Nature       Date:  2014-01-16       Impact factor: 49.962

Review 6.  Cancer chemoresistance; biochemical and molecular aspects: a brief overview.

Authors:  Saeed Kachalaki; Mina Ebrahimi; Leila Mohamed Khosroshahi; Sina Mohammadinejad; Behzad Baradaran
Journal:  Eur J Pharm Sci       Date:  2016-04-16       Impact factor: 4.384

7.  METTL14 promotes the migration and invasion of breast cancer cells by modulating N6‑methyladenosine and hsa‑miR‑146a‑5p expression.

Authors:  Dandan Yi; Ru Wang; Xianbiao Shi; Lei Xu; Yiminu'er Yilihamu; Jianfeng Sang
Journal:  Oncol Rep       Date:  2020-02-24       Impact factor: 3.906

8.  Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2.

Authors:  Qian Zhou; Juan Guo; Wenjie Huang; Xiaosi Yu; Chen Xu; Xinghua Long
Journal:  Mol Oncol       Date:  2020-05-24       Impact factor: 6.603

9.  miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease.

Authors:  Yong-Bo Hu; Yong-Fang Zhang; Hao Wang; Ru-Jing Ren; Hai-Lun Cui; Wan-Ying Huang; Qi Cheng; Hong-Zhuan Chen; Gang Wang
Journal:  Cell Death Dis       Date:  2019-08-05       Impact factor: 8.469

10.  miR-615-3p promotes the epithelial-mesenchymal transition and metastasis of breast cancer by targeting PICK1/TGFBRI axis.

Authors:  Bo Lei; Dandan Wang; Ming Zhang; Yuwei Deng; Huijie Jiang; Yiwen Li
Journal:  J Exp Clin Cancer Res       Date:  2020-04-26
View more
  1 in total

Review 1.  In silico Methods for Identification of Potential Therapeutic Targets.

Authors:  Xuting Zhang; Fengxu Wu; Nan Yang; Xiaohui Zhan; Jianbo Liao; Shangkang Mai; Zunnan Huang
Journal:  Interdiscip Sci       Date:  2021-11-26       Impact factor: 3.492

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.